166 related articles for article (PubMed ID: 27521317)
1. Immunophenotypic Characterization of Cytogenetic Subgroups in Egyptian Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia.
Adnan Awad S; Kamel MM; Ayoub MA; Kamel AM; Elnoshokaty EH; El Hifnawi N
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S19-S24.e1. PubMed ID: 27521317
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia.
Kandeel EZ; Madney Y; Eldin DN; Shafik NF
Exp Mol Pathol; 2021 Feb; 118():104597. PubMed ID: 33358743
[TBL] [Abstract][Full Text] [Related]
3. Significance of CD34/CD123 expression in detection of minimal residual disease in B-ACUTE lymphoblastic leukemia in children.
Zeidan MA; Kamal HM; El Shabrawy DA; Esh AM; Sattar RH
Blood Cells Mol Dis; 2016 Jul; 59():113-8. PubMed ID: 27282579
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.
Popov A; Henze G; Tsaur G; Budanov O; Roumiantseva J; Belevtsev M; Verzhbitskaya T; Movchan L; Lagoyko S; Zharikova L; Olshanskaya Y; Riger T; Valochnik A; Miakova N; Litvinov D; Khlebnikova O; Streneva O; Stolyarova E; Ponomareva N; Novichkova G; Aleinikova O; Fechina L; Karachunskiy A
Cancer Med; 2024 Apr; 13(8):e7172. PubMed ID: 38651186
[TBL] [Abstract][Full Text] [Related]
5. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
[TBL] [Abstract][Full Text] [Related]
9. The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia.
Wang W; Gao L; Li Y; Li ZL; Gong M; Huang FZ; Chen YR; Zhang CX; Gao YY; Ma YG
Leuk Lymphoma; 2016 May; 57(5):1174-81. PubMed ID: 26436205
[TBL] [Abstract][Full Text] [Related]
10. [Expression of CD123 in lymphocytic leukemia and its significance for monitoring minimal residual diseases.].
Wang YF; Chen BG; Luo WD; Zheng R; Li BL
Zhonghua Xue Ye Xue Za Zhi; 2010 Apr; 31(4):244-8. PubMed ID: 20510041
[TBL] [Abstract][Full Text] [Related]
11. No prognostic significance of immunophenotypic changes at the end of remission induction therapy in children with B-lineage acute lymphoblastic leukemia.
Dai Q; Liu X; Yang H; Guo S; Wang Y; Peng L; Ye L; Chen L; Lai C; Chen Q; Zhang G; Jiang Y
Leuk Res; 2018 May; 68():57-61. PubMed ID: 29544133
[TBL] [Abstract][Full Text] [Related]
12. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.
Patkar N; Alex AA; B B; Ahmed R; Abraham A; George B; Vishwabandya A; Srivastava A; Mathews V
Cytometry B Clin Cytom; 2012 Jul; 82(4):252-8. PubMed ID: 22467604
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotypic portrait of leukemia-associated-phenotype markers in B acute lymphoblastic leukemia.
Boris E; Theron A; Montagnon V; Rouquier N; Almeras M; Moreaux J; Bret C
Cytometry B Clin Cytom; 2024 Jan; 106(1):45-57. PubMed ID: 38037221
[TBL] [Abstract][Full Text] [Related]
14. Centrosome Aberration Frequency and Disease Association in B-Acute Lymphoblastic Leukemia.
Kerketta LS; Ghosh K; Nadkarni A; Madkaikar M; Vundinti BR
In Vivo; 2017; 31(2):215-220. PubMed ID: 28358703
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
DiGiuseppe JA; Fuller SG; Borowitz MJ
Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry.
Alm SJ; Engvall C; Asp J; Palmqvist L; Abrahamsson J; Fogelstrand L
Int J Lab Hematol; 2017 Apr; 39(2):121-128. PubMed ID: 28004528
[TBL] [Abstract][Full Text] [Related]
17. An integrated genomic profile that includes copy number alterations is highly predictive of minimal residual disease status in childhood precursor B-lineage acute lymphoblastic leukemia.
Patkar N; Subramanian PG; Tembhare P; Mandalia S; Chaterjee G; Rabade N; Kodgule R; Chopra K; Bibi A; Joshi S; Chaudhary S; Mascerhenas R; Kadam-Amare P; Narula G; Arora B; Banavali S; Gujral S
Indian J Pathol Microbiol; 2017; 60(2):209-213. PubMed ID: 28631637
[TBL] [Abstract][Full Text] [Related]
18. Interference of bone marrow CD56
Theodorakos I; Paterakis G; Papadakis V; Vicha A; Topakas G; Jencova P; Karchilaki E; Taparkou A; Tsagarakis NJ; Polychronopoulou S
Pediatr Blood Cancer; 2019 Aug; 66(8):e27799. PubMed ID: 31066205
[TBL] [Abstract][Full Text] [Related]
19. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients.
Aref S; Azmy E; El-Bakry K; Ibrahim L; Mabed M
Hematology; 2018 Jun; 23(5):263-270. PubMed ID: 29161980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
